Elicio Therapeutics (ELTX) Cash from Operations (2020 - 2026)

Elicio Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 11645000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 15.08% year-over-year to 11645000.0; the trailing twelve-month figure through Mar 2026 stood at 38478000.0 (down 9.73% YoY), and the FY2025 full-year result was 36952000.0, changed 0.31% from the prior year.
• Cash from Operations for Q1 2026 stood at 11645000.0, down from 6797000.0 in the prior quarter.
• The five-year high for Cash from Operations was 6136000.0 in Q2 2022, with the low at 15653000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 8266941.18 across 5 years, with a median of 8928000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 158.27% — and 2023, when it tumbled 254.42%.
• Elicio Therapeutics' Cash from Operations stood at 7276000.0 in 2022, then tumbled by 36.0% to 9895000.0 in 2023, then increased by 11.63% to 8744000.0 in 2024, then increased by 22.27% to 6797000.0 in 2025, then tumbled by 71.33% to 11645000.0 in 2026.
• The last three Cash from Operations figures came in at 11645000.0 (Q1 2026), 6797000.0 (Q4 2025), and 11086000.0 (Q3 2025), per Business Quant data.